Bsc BSc - Gemina Laboratories Chief Sec
| GLABF Stock | USD 0.80 0.03 3.61% |
Insider
Bsc BSc is Chief Sec of Gemina Laboratories
| Age | 63 |
| Phone | 604-760-1997 |
| Web | https://www.geminalabs.com |
Gemina Laboratories Management Efficiency
The company has return on total asset (ROA) of (1.4765) % which means that it has lost $1.4765 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.4671) %, meaning that it generated substantial loss on money invested by shareholders. Gemina Laboratories' management efficiency ratios could be used to measure how well Gemina Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Judith MD | Genmab AS | 65 | |
| Michael Breen | GT Biopharma | 62 | |
| PharmD MBA | GT Biopharma | N/A | |
| Henrik Poulsen | Novo Nordisk AS | 53 | |
| Rudolph Tanzi | Alterity Therapeutics | 66 | |
| Rima Nassar | Genmab AS | 70 | |
| Thomas Schaible | Fortress Biotech Pref | N/A | |
| Adi ZuloffShani | Scisparc | 56 | |
| Marcus Schindler | Novo Nordisk AS | 59 | |
| Michael Esq | Fortress Biotech Pref | 57 | |
| MPH MBA | GT Biopharma | N/A | |
| Samuel Berry | Fortress Biotech Pref | N/A | |
| BSc BSc | Alterity Therapeutics | 69 | |
| Martin Lange | Novo Nordisk AS | 55 | |
| Ido Morpurgo | Purple Biotech | 51 | |
| Steven Targum | Alterity Therapeutics | N/A | |
| BSc FRCPC | Inhibikase Therapeutics | N/A | |
| BBus CA | Alterity Therapeutics | 63 | |
| Nir Livneh | Purple Biotech | 45 | |
| Anthony Mancini | Genmab AS | 52 | |
| Gregory MD | GT Biopharma | 66 | |
Management Performance
| Return On Equity | -3.47 | |||
| Return On Asset | -1.48 |
Gemina Laboratories Leadership Team
Elected by the shareholders, the Gemina Laboratories' board of directors comprises two types of representatives: Gemina Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemina. The board's role is to monitor Gemina Laboratories' management team and ensure that shareholders' interests are well served. Gemina Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemina Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Browning, Head Limited | ||
| Brian Firth, Chief Officer | ||
| Robert Greene, Chief Director | ||
| Bsc BSc, Chief Sec |
Gemina Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Gemina Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.47 | |||
| Return On Asset | -1.48 | |||
| Operating Margin | 979.18 % | |||
| Current Valuation | 17.22 M | |||
| Shares Outstanding | 64.1 M | |||
| Shares Owned By Insiders | 56.28 % | |||
| Price To Book | 9.70 X | |||
| Price To Sales | 5,790 X | |||
| EBITDA | (4.69 M) | |||
| Net Income | (4.73 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Gemina OTC Stock
Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.